Blons, Hélène
Université Paris Cité · Assistance Publique – Hôpitaux de Paris · Hôpital Européen Georges-Pompidou
8 papers on CoChatORCID 0000-0002-0572-8426
Most cited papers
- Verified
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
Mazières, J., Peters, S., Lepage, B., Cortot, A. B., Barlesi, F., Beau-Faller, M., Besse, B., Blons, H., Mansuet-Lupo, A., Urban, T., et al. (2013) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 668
- Verified
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network
Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I., et al. (2014) · Annals of Oncology
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 324
- Verified
Oncogenic mutations as predictive factors in colorectal cancer
Lièvre, A., Blons, H., & Laurent-Puig, P. (2010) · Oncogene
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 117
- Verified
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
Blons, H., Emile, J. F., Le Malicot, K., Julié, C., Zaanan, A., Tabernero, J., Mini, E., Folprecht, G., Van Laethem, J. L., Thaler, J., et al. (2014) · Annals of Oncology
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 108
- Verified
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program
Leduc, C., Merlio, J. P., Besse, B., Blons, H., Debieuvre, D., Bringuier, P. P., Monnet, I., Rouquette, I., Fraboulet-Moreau, S., Lemoine, A., et al. (2017) · Annals of Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 96
- Verified
Intratumor CMS heterogeneity impacts patient prognosis in localized colon cancer
Marisa, L., Blum, Y., Taieb, J., Ayadi, M., Pilati, C., Le Malicot, K., Lepage, C., Salazar, R., Aust, D., Duval, A., et al. (2021) · Clinical Cancer Research
Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer
Cited by 68
- Verified
The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer
Le Corre, D., Ghazi, A., Balogoun, R., Pilati, C., Aparicio, T., Martin-Lannerée, S., Marisa, L., Djouadi, F., Poindessous, V., Crozet, C., et al. (2019) · eBioMedicine
Cancer Cells and MetastasisColorectal Cancer Treatments and Studies
Cited by 48
- Verified
Efficacy and safety of immune checkpoint blockade in patients with Li-Fraumeni syndrome
Bottosso, M., Verret, B., Caron, O., Hamzaoui, N., Pasmant, E., Danlos, F.-X., Boudou-Rouquette, P., Srikaran, A., Blons, H., Guarneri, V., et al. (2024) · JCO Precision Oncology
Cancer Immunotherapy and BiomarkersImmunodeficiency and Autoimmune Disorders
Cited by 6
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free